Navigation Links
Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine
Date:1/5/2011

intends," "estimates," "plans" and similar expressions.  Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.  These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2009.  Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

*Iniparib is the United States Adopted Name (USAN) for the investigational agent BSI-201.Contact: Jack CoxMedia RelationsTel : 908.981.5280

SOURCE sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... ROCKVILLE, Md. , May 22, 2015 /PRNewswire/ ... "RegeneRx") today announced a peer-reviewed publication of the ... study evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for ... Inc.,s controlled adverse environment (CAE ® ) model.  ... and the results, which were previously disseminated by ...
(Date:5/22/2015)... 2015 According to a new ... (Consumables, Instruments, Services), by Test Type (Indirect, Enzyme-based, Reactive ... by End Users - Global Forecast to 2020", published ... to reach $736.85 Million by 2020 from $452.36 Million ... Browse 71 market data Tables and 90 ...
(Date:5/22/2015)... 2015   InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" ... ("EPS"), today announced that its CGuard TM Embolic Prevention ... Prof. Piotr Musialek , at the EuroPCR ... . PARADIGM, an investigator-initiated P rospective ... roti D revascularization I n symptomatic and increased-risk ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... Biodel Inc. (Nasdaq: BIOD ) today announced ... will be presenting at the 6th Annual JMP Securities Healthcare ... presentation is scheduled for Tuesday, September 27, 2011 at 8:30 ... webcast or a replay of the presentation, please visit the ...
... 2011 Reportlinker.com announces that a new ... catalogue: Generic Drugs: The ... http://www.reportlinker.com/p0619265/Generic-Drugs-The-Global-Market--Focus-on-Europe.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Machine_Tool_and_Equipment THIS ... examination of the strategies employed by companies ...
Cached Medicine Technology:Generic Drugs: The Global Market--Focus on Europe 2Generic Drugs: The Global Market--Focus on Europe 3Generic Drugs: The Global Market--Focus on Europe 4Generic Drugs: The Global Market--Focus on Europe 5Generic Drugs: The Global Market--Focus on Europe 6Generic Drugs: The Global Market--Focus on Europe 7Generic Drugs: The Global Market--Focus on Europe 8Generic Drugs: The Global Market--Focus on Europe 9Generic Drugs: The Global Market--Focus on Europe 10
(Date:5/23/2015)... (PRWEB) May 23, 2015 On Saturday, May ... a new playground for Branches Florida City exactly five years ... play space in 2010. , A large fire tore through ... on May 23, 2010 in the middle of the night ... fire was later declared arson even though it is suspected ...
(Date:5/23/2015)... 2015 With the implementation of the ... it increasingly difficult to provide their employees with a ... adequate insurance for employees stand to face strict penalties. ... integral part of a business’s success or failure. In ... Online USA Doctors has created a varying level of ...
(Date:5/23/2015)... AZ (PRWEB) May 23, 2015 Manufacturers are ... Seasonal Performance Factor (HSPF) of 8.2. Experts in the field ... ultimately benefit consumers. , The HSPF score is what miles ... the more efficient the unit. Although the minimum HSPF score ... water heaters with an HSPF score north of 12. Indeed, ...
(Date:5/23/2015)... Add High-Quality prismatic refractions into footage using ... It's as simple as dragging and dropping footage into the ... full effect. , Including over 80 stunning flares, ProFlare ... making this the ultimate bundle for adding prismatic refractions to ... package are movie files designed for Final Cut Pro X, ...
(Date:5/22/2015)... 22, 2015 Pioneer Millworks, the largest ... forefront of designing with reclaimed wood, introducing their latest ... Angeles, California. Their newest offerings, Vat 35, Reclaimed ... and color to America's largest design event. , “Designers, ... each show, anxious to see and feel the variety ...
Breaking Medicine News(10 mins):Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3
... and PARSIPPANY, N.J., July 14 Healthfirst has,contracted ... free online service,for electronic claims submissions. This new ... providers to do business with the health plan,by ... exchange of,information, higher acceptance rates and quicker payment ...
... Disabled Veteran Owned Business Offers Premier Combat Lifesaver ... ... OCEANSIDE, Calif., July 14 In the summer of 2005, ... medical,bag to accommodate the requirements for the Combat Lifesaver program, ...
... July 14 CyberKnife Centers of Miami and Palm,Beach ... Tampa Bay by summer,s,end. MORSE LLC of Miami, a ... the three centers in maintaining the model,of community-based outpatient ... provide the CyberKnife technology to the broadest number of,patients ...
... playing level 83% of time, report shows , , MONDAY, July ... doctors reports that he,s performing more surgeries on sprained elbows ... children focusing on just one sport. , The findings suggest ... putting their arms at risk, said co-author Dr. E. Lyle ...
... Fitness Isn,t Just for PC Users Anymore, SAN ... brain health software, today announced the general availability,of the ... Classic. Over the past,year, the company has received thousands ... benefits of faster thinking, sharper focus, and better memory,and ...
... Second Quarter Sales Increase by 38% as ... -STAAR Surgical Announces New Consumer ... STAAR Surgical,Company (Nasdaq: STAA ) announced today ... lens implanted in the eye to correct,refractive errors, continues ...
Cached Medicine News:Health News:Healthfirst and MD On-Line Partner to Streamline Claims Processing 2Health News:Creator of Recon Moutaineer's Tactical Combat Casualty Care Bag Praises Combat Lifesavers 2Health News:Elbow Injuries on Rise Among Young Athletes 2Health News:Elbow Injuries on Rise Among Young Athletes 3Health News:Posit Science Corporation Releases the Brain Fitness Program Classic(TM) for Mac OS X 2Health News:Alternative to LASIK Increases Momentum with U.S. Consumers 2Health News:Alternative to LASIK Increases Momentum with U.S. Consumers 3Health News:Alternative to LASIK Increases Momentum with U.S. Consumers 4Health News:Alternative to LASIK Increases Momentum with U.S. Consumers 5
... Suture™ VERSAPORT™ PLUS V2 RT single-use obturator has ... shield. , ,The Auto Suture™ VERSAPORT™ PLUS ... -11, 5-12, 11 mm and 12 mm diameters ... mm and 5 mm short single-use obturators are ...
... The Auto Suture™ VERSAPORT™ PLUS RPF trocar ... mm long, 5 mm-11 mm, 5 mm-12 mm, ... sleeve and shield. , ,The VERSAPORT™ PLUS ... a spring-loaded shield. Upon entry into a free ...
The SURGINEEDLE™ is a veress type needle that is used to insufflate the abdomen to create pneumoperitoneum....
... complete line of Surgical Access ...unlike any ... OnePort™ trocar system is actually four systems ... operationally flexible and clinically adaptive to all ... in disposability and bladed or dilating tip ...
Medicine Products: